Table 3: MiR-21 expression level in serum and stool, based on patients’ clinical characteristics.
|
|
|
MiR-21 in serum |
MiR-21 in stool |
||
|
Average rank |
P value |
Average rank |
P value |
||
|
Age |
≤50 |
20.37 |
0.688(>0.05) |
17.25 |
0.151(>0.05) |
|
>50 |
19.90 |
22.67 |
|||
|
Genus |
Male |
19.81 |
0.694(>0.05) |
20.52 |
0.989(>0.05) |
|
Female |
21.26 |
20.47 |
|||
|
Tumor type |
Colon |
21.09 |
0.52(>0.05) |
20.33 |
0.852(>0.05) |
|
Rectum |
18.12 |
20.19 |
|||
|
Tumor size |
≤5cm |
18.88 |
0.38 (>0.05) |
18.52 |
0.250(>0.05) |
|
>5 cm |
22.23 |
22.96 |
|||
|
Tumor location |
Right side |
21.14 |
0.478(>0.05) |
22.00 |
0.212(>0.05) |
|
Left side |
18.53 |
17.41 |
|||
There are no significant association between Stool and Serum MiR-21 expression level and clinical characteristics (age, genus, tumor type, tumor size and tumor location) of colorectal patients (P value >0.05).